EGFR and non-small cell lung carcinoma: Thus, as with the L858R mutation and exon 19 deletions, several expert panels currently state that ctDNA may be used to identify EGFR T790M mutations for predicting response to osimertinib in patients with advanced NSCLC who develop acquired resistance to first generation EGFR-TKIs [43,44,45,46].